JP2015505829A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505829A5
JP2015505829A5 JP2014544867A JP2014544867A JP2015505829A5 JP 2015505829 A5 JP2015505829 A5 JP 2015505829A5 JP 2014544867 A JP2014544867 A JP 2014544867A JP 2014544867 A JP2014544867 A JP 2014544867A JP 2015505829 A5 JP2015505829 A5 JP 2015505829A5
Authority
JP
Japan
Prior art keywords
tissue
ischemia
cells
stem
progenitor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014544867A
Other languages
English (en)
Japanese (ja)
Other versions
JP6106688B2 (ja
JP2015505829A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/066984 external-priority patent/WO2013082241A2/en
Publication of JP2015505829A publication Critical patent/JP2015505829A/ja
Publication of JP2015505829A5 publication Critical patent/JP2015505829A5/ja
Application granted granted Critical
Publication of JP6106688B2 publication Critical patent/JP6106688B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014544867A 2011-12-02 2012-11-29 虚血を処置する改善された方法 Active JP6106688B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161566494P 2011-12-02 2011-12-02
US61/566,494 2011-12-02
PCT/US2012/066984 WO2013082241A2 (en) 2011-12-02 2012-11-29 Improved methods of treating ischemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017041708A Division JP6415616B2 (ja) 2011-12-02 2017-03-06 虚血を処置する改善された方法

Publications (3)

Publication Number Publication Date
JP2015505829A JP2015505829A (ja) 2015-02-26
JP2015505829A5 true JP2015505829A5 (enExample) 2016-01-28
JP6106688B2 JP6106688B2 (ja) 2017-04-05

Family

ID=48536234

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014544867A Active JP6106688B2 (ja) 2011-12-02 2012-11-29 虚血を処置する改善された方法
JP2017041708A Active JP6415616B2 (ja) 2011-12-02 2017-03-06 虚血を処置する改善された方法
JP2018153543A Active JP6727261B2 (ja) 2011-12-02 2018-08-17 虚血を処置する改善された方法
JP2020112693A Withdrawn JP2020158540A (ja) 2011-12-02 2020-06-30 虚血を処置する改善された方法
JP2022070033A Pending JP2022093428A (ja) 2011-12-02 2022-04-21 虚血を処置する改善された方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017041708A Active JP6415616B2 (ja) 2011-12-02 2017-03-06 虚血を処置する改善された方法
JP2018153543A Active JP6727261B2 (ja) 2011-12-02 2018-08-17 虚血を処置する改善された方法
JP2020112693A Withdrawn JP2020158540A (ja) 2011-12-02 2020-06-30 虚血を処置する改善された方法
JP2022070033A Pending JP2022093428A (ja) 2011-12-02 2022-04-21 虚血を処置する改善された方法

Country Status (5)

Country Link
US (3) US10111907B2 (enExample)
EP (2) EP2785350B1 (enExample)
JP (5) JP6106688B2 (enExample)
ES (1) ES2682255T3 (enExample)
WO (1) WO2013082241A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2785834T (pt) 2011-12-02 2020-11-13 Fate Therapeutics Inc Composição de células estaminais melhorada
US10111907B2 (en) * 2011-12-02 2018-10-30 Fate Therapeutics, Inc. Methods of treating ischemia
WO2014093531A1 (en) * 2012-12-11 2014-06-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Modulation of myofiber repair by anti-myostatin in strategies with stem cells
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
WO2014150602A1 (en) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
KR101674253B1 (ko) * 2014-07-16 2016-11-08 연세대학교 산학협력단 트랜스웰 및 케모카인을 이용한 줄기세포의 분리 방법
HK1247958A1 (zh) * 2015-05-05 2018-10-05 菲特治疗公司 T淋巴细胞的调节
KR20180033537A (ko) 2015-07-21 2018-04-03 더 칠드런스 메디칼 센터 코포레이션 Pd-l1 발현 조혈 줄기 세포 및 용도
WO2017026838A1 (ko) * 2015-08-12 2017-02-16 주식회사 차바이오텍 향상된 탯줄 유래 부착형 줄기세포, 그의 제조방법 및 용도
ES2914692T3 (es) 2015-08-12 2022-06-15 Cha Biotech Co Ltd Células madre adhesivas derivadas de cordón umbilical mejoradas, método de preparación para las mismas, y uso de las mismas
JP2018528970A (ja) * 2015-09-16 2018-10-04 サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、(セーエヌエルエス) 悪性腫瘍を治療および/または腫瘍再発を予防するためのゲル化組成物
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
AU2017225999B2 (en) * 2016-03-04 2022-08-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
KR102002671B1 (ko) * 2016-11-11 2019-07-23 사회복지법인 삼성생명공익재단 2dg를 이용한 줄기세포 역량 향상 방법
CA3065945A1 (en) 2017-06-09 2018-12-13 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing or treating muscle conditions
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
WO2019102761A1 (ja) 2017-11-24 2019-05-31 Kyb株式会社 筒型リニアモータ
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds
CN116966302B (zh) * 2023-06-28 2025-11-25 华中科技大学同济医学院附属协和医院 Areg的新用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5420033A (en) 1989-06-21 1995-05-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Epithelial cell line expressing a cystic fibrosis phenotype
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
DK0423980T3 (da) 1989-10-16 2000-10-09 Amgen Inc Stamcellefaktor
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
AU2882992A (en) 1991-11-06 1993-06-07 Arthur A. Axelrad Cell culture medium
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
US5442033A (en) 1993-07-20 1995-08-15 Ethicon, Inc. Liquid copolymers of epsilon-caprolactone and lactide
WO1995006112A1 (en) 1993-08-23 1995-03-02 Baxter International Inc. In vitro growth of neutrophil and megakaryocyte precursors in serum-free media
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5648331A (en) 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5753516A (en) 1995-02-03 1998-05-19 Heagy; Wyrta E. Screening method for ligands of the EBI-1 receptor
WO1996040866A1 (en) 1995-06-07 1996-12-19 Novartis Ag Serum-free media for primitive hematopoietic cells and methods of use thereof
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5945337A (en) 1996-10-18 1999-08-31 Quality Biological, Inc. Method for culturing CD34+ cells in a serum-free medium
US6372796B1 (en) 1996-11-13 2002-04-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
US6191109B1 (en) 1997-10-31 2001-02-20 Children's Hospital, Inc. Methods of treating intestinal ischemia using heparin-binding epidermal growth factor
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
GB9904281D0 (en) 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
EP1219600A4 (en) 1999-08-13 2004-11-03 Taisho Pharmaceutical Co Ltd PROSTAGLANDIN DERIVATIVES
TWI247606B (en) 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
BR0015781A (pt) 1999-11-24 2002-12-31 Ono Pharmaceutical Co Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
PT1132086E (pt) 2000-01-31 2006-09-29 Pfizer Prod Inc Utilizacao de agonistas selectivos para o receptor da prostaglandina (pge2) 4 (ep4) para o tratamento de falha renal aguda e cronica
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
US7179643B2 (en) 2001-06-14 2007-02-20 Reliance Life Sciences Pvt. Ltd. Device and a process for expansion of haemopoeitic stem cells for therapeutic use
IL162648A0 (en) 2001-12-21 2005-11-20 Mount Sinai Hospital Corp Cellular compositions and methods of making and using them
EP1563846B1 (en) 2002-10-10 2012-08-29 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production promoters
JP2006519250A (ja) 2003-03-04 2006-08-24 ファイザー・プロダクツ・インク 医療処置におけるep2選択的受容体アゴニストの使用
AU2004217699B2 (en) 2003-03-07 2008-07-03 Gamida-Cell Ltd. Expansion of renewable stem cell populations using modulators of PI 3-kinase
WO2004081196A2 (en) 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
US8309608B2 (en) 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
US8328876B2 (en) 2003-12-31 2012-12-11 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
JP4086816B2 (ja) 2004-07-01 2008-05-14 株式会社Nec情報システムズ Bga部品搭載基板の層数見積もり装置及び方法並びに層数見積もりプログラム
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
EP2360242A1 (en) 2004-09-24 2011-08-24 Angioblast Systems, Inc. Method of enhancing proliferation and/or survival of mesenchymal procursor cells (MPC)
JP2008518013A (ja) 2004-10-26 2008-05-29 アラーガン、インコーポレイテッド プロスタグランジンep4アゴニストによる処置方法およびデリバリー方法
WO2006078886A2 (en) 2005-01-18 2006-07-27 Irm Llc Compounds and compositions as wnt signaling pathway modulators
EP1859028B1 (en) 2005-02-10 2015-12-02 Regents Of The University Of Minnesota Vascular endothelial cells
US20090220465A1 (en) 2005-11-07 2009-09-03 The General Hospital Corporation Methods and compositions for modulation of stem cell aging
DE102005062741A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorene und Carbazole als Liganden des EP2 Rezeptors
AU2006326853B2 (en) 2005-12-22 2012-02-16 Es Cell International Pte Ltd Direct differentiation of cardiomyocytes from human embryonic stem cells
MX373998B (es) 2006-03-24 2020-07-22 Childrens Medical Center Uso de un modulador de células madre hematopoyeticas (hsc) para promover el crecimiento de hsc.
US20100233135A1 (en) 2006-08-16 2010-09-16 The General Hospital Corporation Compositions and methods for hematopoietic stem cell expansion or for modulating angiogenesis
KR20080042761A (ko) 2006-11-10 2008-05-15 문찬일 렙틴을 이용한 줄기세포 증식방법
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
US8871752B2 (en) 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
WO2009134532A2 (en) 2008-03-07 2009-11-05 The Trustees Of Columbia University In The City Of New York Homing in mesenchymal stem cells
US8092822B2 (en) * 2008-09-29 2012-01-10 Abbott Cardiovascular Systems Inc. Coatings including dexamethasone derivatives and analogs and olimus drugs
EP3031907B1 (en) 2008-11-06 2021-01-06 Indiana University Research and Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
EP2367432B1 (en) * 2008-12-03 2017-08-30 Amorcyte, Inc. Infarct area perfusion-improving composition
EP3533445A1 (en) 2009-03-19 2019-09-04 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
ES2727787T3 (es) * 2009-11-15 2019-10-18 Univ Indiana Res & Tech Corp Métodos para mejorar el suministro y el injerto de células madre incluida la identificación de receptores específicos de prostaglandina E2
EP2603227B1 (en) 2010-08-12 2017-10-04 Fate Therapeutics, Inc. Improved hematopoietic stem and progenitor cell therapy
US10111907B2 (en) * 2011-12-02 2018-10-30 Fate Therapeutics, Inc. Methods of treating ischemia
PT2785834T (pt) 2011-12-02 2020-11-13 Fate Therapeutics Inc Composição de células estaminais melhorada

Similar Documents

Publication Publication Date Title
JP2015504313A5 (enExample)
Li et al. Mechanism and application of exosomes in the wound healing process in diabetes mellitus
JP6483187B2 (ja) 増強された幹細胞組成物
JP6415616B2 (ja) 虚血を処置する改善された方法
JP2019187429A5 (enExample)
US10702556B2 (en) Compositions and methods for inducing angiogenesis
JP2021036918A5 (enExample)
Campbell et al. The good, bad, and the ugly of regenerative therapies for erectile dysfunction
Volpe et al. Efficacy of cord blood platelet gel application for enhancing diabetic foot ulcer healing after lower limb revascularization
James et al. Can we fix it? Evaluating the potential of placental stem cells for the treatment of pregnancy disorders
US10383895B2 (en) Stimulation of therapeutic angiogenesis by T regulatory cells
Tracy et al. State of the field: cellular and exosomal therapeutic approaches in vascular regeneration
Murata Prophylactic and therapeutic treatment of graft-versus-host disease in Japan
Dabravolski et al. Preclinical and mechanistic perspectives on adipose-derived stem cells for atherosclerotic cardiovascular disease treatment
Dorofeeva et al. Efficacy of various combined treatment regimens in patients with stable effort angina, functional classes II-III
Ricart et al. Cell therapies for IBD: what works?
Tonkin et al. Healing the ischaemic heart: a critical review of stem cell therapies
US12145984B2 (en) Methods for preventing ischemia reperfusion injury in an organ with antibody antagonists of IL-33
Ramos et al. Mesenchymal stem cells for recurrent miscarriage
Lee et al. Muslin-induced intracranial vasculopathic stenosis: a report of two cases
RU2649498C1 (ru) Способ лечения ишемической ангиопатии сосудов нижних конечностей
Corey et al. Brain Hemorrhages
Kurtzberg et al. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal®) as a rescue agent for severe refractory acute GVHD in pediatric patients
Mishima et al. Experimental and Clinical Research
Bhat et al. From Trials to Therapeutics: are Mesenchymal Stem Cells Promising in Cellular Therapy?